You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Details for Patent: 10,722,473


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,722,473 protect, and when does it expire?

Patent 10,722,473 protects ADHANSIA XR and is included in one NDA.

Summary for Patent: 10,722,473
Title:Methods and compositions particularly for treatment of attention deficit disorder
Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
Inventor(s): Donnelly; Graeme (Toronto, CA), Bhaskar; Sailaja (Pickering, CA)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:16/195,418
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,722,473: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article will delve into the details of United States Patent 10,722,473, examining its claims, the patent landscape, and the implications of its scope.

Patent Overview

United States Patent 10,722,473, though not specifically detailed in the provided sources, can be analyzed using general principles of patent law and research methodologies.

Patent Number and Title

To begin, identify the patent number (10,722,473) and the title of the patent. This information is crucial for searching and understanding the patent's subject matter.

Inventors and Assignees

Knowing the inventors and assignees can provide insights into the patent's origins and potential applications. This information is typically found in the patent document itself.

Claims Analysis

Independent and Dependent Claims

Patent claims are the heart of any patent, defining the scope of protection. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims, often adding specific details or limitations[3].

  • Independent Claims: These claims should be examined to understand the core invention. For example, if the patent is related to a technological device, the independent claims might describe the overall structure and function of the device.
  • Dependent Claims: These claims narrow down the invention by adding specific features or embodiments. They often provide additional details that can help in understanding the full scope of the invention.

Claim Construction

Claim construction is the process of interpreting the meaning of the claims. This involves analyzing the claim language, the specification, and any relevant prosecution history. The courts and the USPTO use various tools, such as the "plain and ordinary meaning" rule, to interpret claim terms[1].

Patent Scope

Patent Scope Measurements

The scope of a patent can be measured using various metrics, such as the number of claims, the breadth of the claims, and the dependency relationships between claims. The USPTO's Patent Claims Research Dataset provides tools to analyze these aspects, including claim-level statistics and document-level statistics[3].

  • Claim Breadth: Broader claims provide wider protection but are more susceptible to invalidation. Narrower claims are more specific but offer less protection.
  • Dependency Relationships: Understanding how dependent claims relate to independent claims can help in mapping the overall scope of the patent.

Patent Term and Adjustments

The patent term, typically 20 years from the filing date of the earliest non-provisional application, can be adjusted due to delays in the prosecution process. Patent Term Adjustments (PTA) and Patent Term Extensions (PTE) can extend the life of a patent, but these must be carefully considered in the context of obviousness-type double patenting (ODP)[1].

Patent Landscape

Related Patents and Applications

To understand the patent landscape, it is essential to identify related patents and applications. This includes searching databases such as the USPTO's Patent Public Search, the Cooperative Patent Classification (CPC) database, and international databases like PATENTSCOPE[4].

  • Family Members: Identifying other patents in the same family, such as continuations, continuations-in-part, and divisionals, can provide a comprehensive view of the inventor's contributions.
  • Cited References: Analyzing the patents and publications cited during the prosecution can reveal the state of the art at the time of filing.

Competitors and Market Impact

Understanding the competitive landscape involves identifying other players in the field who may hold similar or overlapping patents. This can be done through advanced patent searching techniques and analyzing market trends.

Legal Implications

Obviousness-Type Double Patenting (ODP)

ODP is a critical issue that can invalidate claims if they are deemed obvious variants of earlier-granted patents from the same inventive entity. The case of In re Cellect highlights the importance of ODP analysis in patent validity[1].

  • ODP Analysis: This involves comparing the claims of the patent in question with those of earlier-granted patents to determine if the later claims are obvious variations.
  • Terminal Disclaimers: In some cases, inventors may file terminal disclaimers to avoid ODP issues, but this must be done carefully to avoid unintended consequences.

Litigation and Enforcement

Patent litigation often revolves around the interpretation of claims and the scope of protection. Understanding the claims and scope of a patent is essential for enforcing patent rights and defending against infringement claims.

Practical Applications

Licensing and Collaboration

The scope and claims of a patent can significantly impact licensing agreements and collaborative efforts. Broad claims may be more attractive for licensing, but they also come with higher risks of invalidation.

Innovation and R&D

For companies involved in research and development, understanding the patent landscape and the scope of existing patents can guide innovation efforts. It helps in identifying areas where new inventions can be developed without infringing existing patents.

Key Takeaways

  • Claims Analysis: Independent and dependent claims define the scope of protection.
  • Patent Scope: Metrics such as claim breadth and dependency relationships help in understanding the patent's scope.
  • Patent Landscape: Identifying related patents and applications is crucial for understanding the competitive environment.
  • Legal Implications: ODP analysis and terminal disclaimers are important for maintaining patent validity.
  • Practical Applications: Licensing, collaboration, and innovation efforts are all influenced by the scope and claims of a patent.

FAQs

Q: What is the significance of independent and dependent claims in a patent?

A: Independent claims define the invention broadly, while dependent claims add specific details or limitations, narrowing down the invention.

Q: How is the scope of a patent measured?

A: The scope can be measured using metrics such as the number of claims, claim breadth, and dependency relationships between claims.

Q: What is obviousness-type double patenting (ODP), and why is it important?

A: ODP is a legal doctrine that can invalidate claims if they are deemed obvious variants of earlier-granted patents from the same inventive entity. It is crucial for maintaining patent validity.

Q: How can one search for related patents and applications?

A: Using databases such as the USPTO's Patent Public Search, the Cooperative Patent Classification (CPC) database, and international databases like PATENTSCOPE.

Q: What are the practical implications of understanding the scope and claims of a patent?

A: It guides licensing agreements, collaborative efforts, and innovation by identifying areas where new inventions can be developed without infringing existing patents.

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. Ex Parte Knight, Casetext.
  3. Patent Claims Research Dataset, USPTO.
  4. Advanced Patent Searching, Clemson University Library Guides.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,722,473

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-001 Feb 27, 2019 DISCN Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try for Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-002 Feb 27, 2019 DISCN Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try for Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-003 Feb 27, 2019 DISCN Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try for Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-004 Feb 27, 2019 DISCN Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try for Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-005 Feb 27, 2019 DISCN Yes No ⤷  Try for Free ⤷  Try for Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.